Repligen Corp RGEN
Analyst Ratings
- Consensus
- Buy — 11 Buy · 1 Hold · 0 Sell (12 analysts)
- Avg. Price Target
- $171.50 (-1.8% downside)
Key Stats
- Today's Range
- $168.27 – $175.85
- 50-Day Range
- $129.00 – $188.73
- 52-Week Range
- $100.99 – $188.73
- Volume
- 891K shs
- Average Volume
- 979K shs
- Market Cap
- $9.48 billion
- P/E Ratio
- 239.36
- Dividend Yield
- —
Valuation
- P/E Ratio
- 239.36
- Price / Book
- 4.49
- Price / Sales
- 12.08
Short Interest
- Short Interest
- 7.13%
- Days to Cover
- 17.37
Financials (TTM)
- Revenue
- $785.10 million
- Net Income
- $41.54 million
- Net Margin
- 5.29%
- Return on Equity
- 1.97%
- Debt-to-Equity
- 0.26
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Related Stocks
Compare head-to-head: RGEN vs AMGN·RGEN vs MRNA·RGEN vs HALO·RGEN vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.